DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.
Generic Entry Opportunity Date for 203971
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 203971
|Mechanism of Action||alpha-Particle Emitting Activity |
Suppliers and Packaging for NDA: 203971
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;INTRAVENOUS||Strength||162mCi/6ML (27mCi/ML)|
|Approval Date:||May 15, 2013||TE:||RLD:||Yes|
|Patent:||Start Trial||Patent Expiration:||Nov 17, 2022||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE|
Complete Access Available with Subscription